Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

, the potential for 2 flare-free years could represent a fundamental shift in what GPP treatment can offer.

 interview with Neal Bhatia, MD, who reflected on the maintenance data emerging from the GEMINI trials for imsidolimab, Vanda Pharmaceuticals' investigational interleukin (IL)-36 receptor inhibitor currently under 

US Food and Drug Administration (FDA) review

 with a PDUFA target date of December 12, 2026.

"You can imagine what that does to quality of life," Bhatia said of the roughly 2-year maintenance period without flares observed in the active treatment arm. Bhatia contrasted this with the limitations of older systemic options such as cyclosporine, characterizing them as slow-acting and burdened by tolerability concerns. These were considered drugs addressing GPP incompletely. The GEMINI data, in Bhatia’s view, represents a meaningful opportunity to extinguish flares that prior treatment paradigms could not reliably control.

On the question of where imsidolimab could fit within the treatment landscape if approved by FDA officials, Bhatia positioned it alongside spesolimab, the currently approved IL-36 inhibitor for GPP, as a natural companion in that targeted class. He acknowledged the real-world tendency among some clinicians to initiate treatment with IL-17 or IL-23 inhibitors given their accessibility and familiarity, but framed that only as a potential bridge. Getting patients to use an IL-36–modifying therapy, Bhatia expressed, should remain the clinical objective.

The therapy's reported favorable safety profile and low incidence of anti-drug antibody formation also carry practical weight in Bhatia's view, though he highlighted his own view suggesting none of it matters without an accurate diagnosis in hand. He recommended patients carry documentation of their confirmed GPP diagnosis to facilitate appropriate care in emergency or urgent care settings where treating clinicians may be unfamiliar with the condition. Equally important, he stressed, is ensuring these individuals have rapid access to infusion therapy at GPP flare onset.

Bhatia closed with a broader call to action for dermatologists, to advocate for GPP patients, embrace emerging targeted drugs, and resist ceding ground on rare inflammatory skin diseases to other specialties.

“This is a rare disease," Bhatia said. "This is not just a variant of psoriasis that I can try to knock down with other therapies that I have samples of."

The quotes contained in this interview summary were edited for clarity.

Bhatia reported serving as an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals.

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis. Vanda Pharmaceuticals, Inc. February 25, 2026. 

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.html

Bhatia N. What Is the Significance of New Data on Imsidolimab for GPP? With Neal Bhatia, MD. HCPLive. March 10, 2026. Accessed March 11, 2026. 

https://www.hcplive.com/view/what-the-significance-new-data-imsidolimab-gpp-neal-bhatia-md

Videos

This segment of Bhatia's interview highlights imsidolimab's reported durability of response for those with generalized pustular psoriasis (GPP).

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Division of Nephrology in the Department of Medicine at Columbia University Irving Medical Center and the Columbia University Renal Epidemiology (CURE) Group in New York

New findings from a cohort study, which identified 15,602 kidneys from 8544 donors in which > 1 kidney was transplanted out of sequence, meaning it bypassed standard allocation order, is occurring earlier, more broadly, and with less justification than its stated rationale supports.

Overall, investigators observed that out-of-sequence kidney transplants reached 4,595 in 2024, nearly 1 in 4 (22.6%) of all deceased donor kidney transplants, representing an approximate 10- to 17-fold growth across all out-of-sequence categories since 2020.

Study investigators defined out-of-sequence allocation by the presence of specific operational refusal codes appearing earlier in the match run than the eventual organ acceptance code. The primary comparison group consisted of unilateral out-of-sequence cases, donors from whom 1 kidney was placed through standard in-sequence allocation and the other was placed out of sequence, allowing for a paired analysis that controls for donor-level quality factors.

Unilateral out-of-sequence transplants, the fastest-growing category, increased 17-fold and accounted for 38.2% of all out-of-sequence transplants by the end of the study period.

The median sequence number at which OPOs first switched to out-of-sequence allocation dropped from 393 in 2020 to just 28 in 2024 for unilateral out-of-sequence cases. According to investigators, this means OPOs are bypassing the standard allocation list almost immediately, well before the point at which a kidney could be considered difficult to place. The number of transplant centers receiving offers before the out-of-sequence switch also decreased, from a median of 14 in 2020 to 10 in 2024.

In 50.5% of cases, 1 kidney from a donor was placed successfully through standard allocation, while the other kidney from the same donor was placed out of sequence. This unilateral pattern directly undermines the commonly cited rationale that out-of-sequence allocation is driven by organ quality concerns or donor-related factors, since both kidneys from a donor would be expected to have comparable underlying characteristics, explains investigators.

Median KDPI scores remained relatively constant across the study period and spanned the full 1% to 100% range, further suggesting organ quality is not the primary driver of these decisions.

Recipients of unilateral out-of-sequence kidneys were disproportionately older, male, White or Asian, privately insured, more highly educated, and more likely to have received a preemptive transplant, before starting dialysis, compared with recipients of the in-sequence kidney from the same donor.

For example, 17.1% of out-of-sequence recipients had a preemptive transplant versus 10.2% of in-sequence recipients (

< .001), and 29.1% had private insurance versus 23.0% (

 < .001). These patterns suggest that the out-of-sequence pathway is consistently benefiting more socioeconomically advantaged patients.

If OPOs were bypassing standard allocation primarily to ensure efficient placement, one would expect out-of-sequence kidneys to go to the same center that accepted the paired in-sequence kidney. Instead, the vast majority (85.7%) of out-of-sequence kidneys went to a different center, and traveled significantly farther (median 171 vs. 99 nautical miles), resulting in greater cold ischemia time, not less. Only 14.8% of unilateral out-of-sequence kidneys in 2024 went to the same center that received the partner kidney.

In adjusted Cox proportional hazards models, there were no statistically significant differences in patient survival (adjusted HR, 0.84; 95% CI, 0.70–1.02; P = .08) or death-censored graft survival (adjusted HR, 0.87; 95% CI, 0.70–1.08; P = .20) between unilateral out-of-sequence and unilateral in-sequence recipients. This held across both low- and high-KDPI groups. The additional flexibility created for transplant centers by the out-of-sequence pathway thus does not appear to translate into measurable improvements in transplant outcomes, as noted by study investigators.

spoke with study investigators Miko Yu, MD, from the Division of Nephrology in the Department of Medicine at Columbia University Irving Medical Center and the Columbia University Renal Epidemiology (CURE) Group in New York, and Joel Adler, MD, MPH, an Assistant Professor of Surgery, Division of Transplant Surgery, Department of Surgery and Perioperative Care at the Dell Medical School.

HCPLive: The central design of your study compares two kidneys from the same donor: one placed in sequence, one out of sequence. When you looked at how early in the match run OPOs were triggering out-of-sequence allocation for that second kidney, what did that tell you about whether organ quality is actually what's driving these decisions?

Yu: I think our findings call into doubt whether organ quality is truly driving these decisions. In the study we also looked at the refusal reasons for these types of kidneys and it does seem that the documented reasons are not overwhelmingly due to donor or organ related concerns such as donor history, biopsy findings or organ damage/mismatch, which you might expect if that second kidney went out of sequence very early on in the match run process.

HCPLive: If donor quality isn't the primary explanation, what is? You've seen the refusal code data, you've seen how uniformly this practice expanded across all 56 OPOs and across the full KDPI spectrum in just four years, what do you think is actually happening on the ground when an OPO decides to go out of sequence?

Yu: Speaking only from a data standpoint, it’s difficult to tease out and each OPO may have its own thresholds/procedures when deciding to go out of sequence. We have also shown in our other papers that there are certain common OPO and transplant center relationships (which are not necessarily geographically close to each other) that may also factor into their decisions when opting for the out of sequence pathway.

Adler: It is a complex problem that has long been managed through largely informal solutions. OPOs and transplant centers are operating under multiple external pressures, and when those pressures are not clearly aligned with shared goals, workarounds are almost inevitable.

HCPLive: Your data show that compared to recipients of the in-sequence mate kidney, out-of-sequence recipients were significantly more likely to be privately insured, more educated, and to have received a preemptive transplant. For patients who are lower on the waitlist, who may have been on dialysis for years and are waiting their turn, what is the real-world consequence of a kidney being pulled out of sequence before it ever reaches them?

Yu: The most immediate consequence would be that these patients who may have been waiting longer are skipped over for suitable offer for a kidney. Also, when a kidney goes out of sequence, transplant centers that were bypassed may not be aware at all that they received an offer for a kidney for their patients. So without a clear mechanism for expedited allocation, it’s not hard to see how the current practice can undermine overall trust in the organ allocation system.

HCPLive: Your adjusted survival analysis found no significant difference in patient or graft outcomes between the two groups. Does that finding vindicate the practice, complicate it, or neither , and what would you need to see in future data to feel confident drawing conclusions either way?

Yu: I think when we look at all the results together—that the in-sequence kidney in this set was by definition successfully placed via the standard allocation system, that there is no significant difference in outcomes between the groups, and that there are disparities in who receives a unilateral out of sequence transplant— it certainly brings up concerns about subjectivity in current out of sequence practices.

Adler: Trust is incredibly important. Even when transplant centers and OPOs are acting in good faith, opaque or inconsistently applied practices can still undermine public trust.

HCPLive: Right now there is no standardized threshold, no required justification, and no oversight mechanism governing when an OPO can go out of sequence. Given everything your study found, what is the single most important thing that would need to change, in policy, in data collection, or in accountability, before this practice can be considered equitable?

Yu: You’re right, I think all these factors – a standardized threshold, required justification and an oversight mechanism—should be incorporated or at least taken into account when we decide on future policies for an expedited allocation pathway. That said, I’m certain what happens the ground gets to be complicated so I’ll defer to Joel on this one.

From a data standpoint, I think refusal reasons could be captured better—there is a large proportion that are categorized as “Other” which further add to the lack of transparency.

Adler: At the end of the day, there is very little debate that some form of rescue or expedited allocation pathway is needed. The challenge is deciding how to implement it, how to monitor it, and how to remain flexible as conditions change. That will only become harder with a rapidly evolving donor pool, increased federal oversight, and greater media scrutiny—but it is exactly the work the field needs to do to move forward while maintaining public trust.

Editor’s Note: Adler reports relevant disclosures with RTI International. Yu reports no relevant disclosures. 

Yu ME, Husain SA, Tucker EG, et al. Expedited Transplant Allocation Using a Paired Kidney Cohort. 

https://doi.org/10.1001/jamanetworkopen.2026.0257

Adler JT, Sharma S. Out of sequence allocation: a necessary innovation or a new inequity in transplantation? 

. Published online September 1, 2024. doi:

https://doi.org/10.1016/j.ajt.2024.09.022

Articles

Out-of-sequence deceased-donor kidney placement expanded rapidly from 2020–2024, reaching 22.6% of transplants in 2024, with unilateral out-of-sequence cases driving growth. OPOs initiated bypass increasingly early in the match run, often after few center offers, and frequently when the mate kidney was successfully placed in-sequence—undermining organ-quality rationales. KDPI distributions were stable across the spectrum. Recipients skewed toward socioeconomically advantaged profiles, while organs traveled farther with longer cold ischemia. Adjusted patient and graft outcomes were similar, elevating equity and transparency concerns.

Yu, MD, Adler, MD, share their perspectives from a cohort study on in-sequence, and out of sequence paired kidneys transplants. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Is Expedited Kidney Donation More Effective Than In-Sequence?

Vice Chief of Education, Fellowship Program Director

Division of Gastroenterology and Hepatology at UNC Health Care

Can Crohn’s Induction Move Beyond Infusions? AFFIRM Trial Insights

New data from the AFFIRM trial suggest that a fully subcutaneous induction strategy with risankizumab (Skyrizi) may deliver strong efficacy while offering a more convenient treatment pathway for patients with Crohn’s disease, adding to the growing body of evidence supporting IL-23 inhibition in this patient population.

First approved for Crohn’s disease in 2022, risankizumab has historically required intravenous induction before transitioning to subcutaneous maintenance dosing. In an interview discussing the AFFIRM results, lead investigator Millie Long, MD, MPH, chief of the division of gastroenterology and hepatology at the University of North Carolina, Chapel Hill noted that evaluating a subcutaneous induction approach represents an important step toward making effective therapy more accessible.

“Previously, risankizumab had been incredibly promising,” Long told 

. “This is obviously an approved agent, but it required IV induction, and so now allowing for a very effective therapy in a subcutaneous load allows us to reach more patients and to potentially get drug in the hands of patients quicker in terms of not having to wait for infusion center chairs, and hopefully will allow us to improve outcomes for those patients.”

The global, phase 3, randomized, placebo-controlled, double-blind AFFIRM study assessed the efficacy and safety of risankizumab SC as an induction treatment in adult patients with moderately to severely active Crohn's disease, with co-primary endpoints of percentage of participants with CDAI Clinical Remission (CDAI < 150) and percentage of participants with endoscopic response at week 12.

“In any induction clinical trial, we look at co primary endpoints, meaning we want to make sure that patients are feeling better in terms of clinical remission, but we also want to make sure that there is an endoscopic response, meaning that the actual inflammation visualized at the level of the endoscopy is improving,” Long explained.

In AFFIRM, a total of 289 patients were randomly assigned in a 2:1 ratio to risankizumab SC or placebo. Results showed significantly greater proportions of patients treated with risankizumab SC induction achieved CDAI clinical remission (55% vs 30%; P <.0001) and endoscopic response (44% vs 14%; P <.0001) at week 12 compared to placebo. Among patients with clinical response after 12 weeks of risankizumab SC induction treatment followed by 12 weeks of maintenance, 67% achieved CDAI clinical remission at week 24 and 57% achieved endoscopic response at week 24.

Long called attention to results in the advanced therapy-naïve population of the study, noting those treated with subcutaneous risankizumab achieved a 73.1% clinical remission rate and a 61.2% endoscopic response rate. She additionally cited encouraging results in patients with prior advanced therapy failure, further supporting risankizumab’s efficacy across patient populations. However, with the particularly strong results in biologic-naïve patients, Long suggests it may have potential as a first-line advanced therapy option in Crohn’s disease.

During the 12-week, double-blind, placebo-controlled period, the safety profile of risankizumab SC was consistent with the safety profile observed in Crohn's disease with no new safety risks observed.

Although the AFFIRM trial focused on a 12-week induction period, Long emphasized that durability and long-term safety data for risankizumab are supported by the broader clinical program evaluating the therapy and the IL-23 inhibitor class.

“The entire risankizumab portfolio and program now has many years of use and that's where the safety data really shine, that this is a highly effective, very safe drug where we're not seeing significant adverse effects in terms of infectious complications, we're not seeing malignancy risks, and really that long term data are what is so reassuring for the risankizumab portfolio,” Long said.

Editors’ Note: Long reports relevant disclosures with AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly, Intercept, Janssen, Pfizer, Prometheus, Roivant, Sanofi, Takeda, and Target RWE.

Brooks A. AFFIRM: Risankizumab (Skyrizi) Subcutaneous Induction Achieves Primary Endpoints in Crohn’s Disease. HCPLive. March 2, 2026. Accessed March 11, 2026. 

https://www.hcplive.com/view/affirm-risankizumab-skyrizi-subcutaneous-induction-achieves-primary-endpoints-in-crohn-s-disease

Walter, K. FDA Approves Risankizumab For Crohn’s Disease. HCPLive. June 17, 2022. Accessed March 11, 2026. 

https://www.hcplive.com/view/fda-appropves-risankizumab-crohns-disease

Long discusses AFFIRM data showing strong clinical and endoscopic outcomes with SC risankizumab (Skyrizi) induction in Crohn’s disease.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

Omalizumab or Oral Immunotherapy for Food Allergy, With Robert Wood, MD

Stage 3 data from the OUtMATCH trial established that both omalizumab and multi-food oral immunotherapy (OIT) enabled successful dietary consumption of allergenic foods in more than 60% of dietary consumption (DC) plans at 12 months with no significant differences between groups — but the tolerability gap separating the 2 treatments remains a central factor patient decision making.

sat down with Robert A. Wood, MD, Chief of the Eudowood Division of Pediatric Allergy and Immunology at Johns Hopkins Children's Center and Professor of Pediatrics at the Johns Hopkins University School of Medicine in Baltimore at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, from February 27 to March 2, where he presented the latest data from OUtMATCH, to learn more.

Of 81 eligible OUtMATCH participants, 80 qualified for DC plans following mOIT (n = 29) or omalizumab (n = 51), covering 83 and 139 individual allergen DC plans respectively. Success was defined as consuming a median of ≥300 mg/day of allergenic food at both 3 and 6 months by daily diary, with additional study team evaluations across all 12 months. By daily diary, DC success rates across all foods were statistically equivalent between groups at both 3 months (post-mOIT 77% vs. post-omalizumab 66%; 

= .77), with peanut-specific outcomes following the same pattern (

Study evaluations told a consistent story across all 12 months — success rates tracked closely between arms at every timepoint (post-mOIT: 90%, 82%, 75%, 67%; post-omalizumab: 91%, 82%, 69%, 63%; 

 = .44–1.00) with no differences on individual allergen analysis (

= .13–1.00). Among the 52 participants who maintained DC plans for all three foods through 12 months (n = 22 post-mOIT; n = 30 post-omalizumab), adverse event rates were similar — 86% (19/22) post-mOIT and 93% (28/30) post-omalizumab — with 2 serious adverse events during the open feeding transition from mOIT and 1 case of eosinophilic esophagitis post-omalizumab.

Wood discussed the practical treatment decision framework he applies in clinic, where omalizumab's ability to block all IgE-mediated reactions regardless of the specific trigger gives it a meaningful advantage for multi-food allergic patients over OIT protocols that require daily consumption of each individual allergenic food. OIT remains competitive for patients with a single dominant allergy, particularly peanut, where an FDA-approved product exists, but no FDA-approved multi-allergen OIT product currently exists, adding regulatory and practical complexity.

“With the oral immunotherapy, we know from all kinds of different studies that some patients will have reactions to the treatment. The reactions can be very trivial, or they can be enough that it's impossible to continue the treatment. So when we're sort of balancing the risk versus benefit,” Wood said.

Looking ahead, Wood was direct that no meaningfully new options are likely within 4 to 5 years as next-generation approaches remain in early-phase investigation, while the 10-year horizon, with potentially up to 10 distinct treatment options in the pipeline, promises to fundamentally reshape how clinicians and families navigate food allergy management together.

Wood’s disclosures include Aimmune, ALK, DBV Technologies, FARE, Genentech, NIAID, Novartis, Regeneron, Siolta, and Aravax.

1. Chinthrajah RS, Lanser B, Leung D, et al. Evaluation of dietary consumption feasibility following treatment with multi-food oral immunotherapy or omalizumab in OUtMATCH. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #L22

2. Smith T. FDA Approves Omalizumab as First Treatment of 1 or More Food Allergies for Children, Adults. Article. HCPLive. February 16, 2024. 

https://www.hcplive.com/view/fda-approves-omalozumab-first-treatment-of-1-or-more-food-allergies-for-children-adults

3. FDA. PALFORZIA. Updated August 1, 2024. 

https://www.fda.gov/vaccines-blood-biologics/allergenics/palforzia

Wood discussed factors that go into shared decision making for multi-food allergy.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Daniel DiGiacomo, MD, a clinical immunologist at Hackensack Meridian Jersey Shore University Medical Center.

AI, Genetic Testing May Advance Precision Care in Immunology, With Daniel DiGiacomo, MD

2026 American Academy of Allergy, Asthma & Immunology (AAAAI) 

annual meeting in Philadelphia, Daniel DiGiacomo, MD, a clinical immunologist at Hackensack Meridian Jersey Shore University Medical Center, discussed how emerging artificial intelligence (AI) technologies could complement genetic testing and help clinicians better understand complex immune disorders.

, DiGiacomo explained that AI may help clinicians interpret the growing volume of genetic data now available in clinical practice, particularly for rare immune conditions known as Inborn Errors of Immunity. Although advances in sequencing have accelerated the discovery of single-gene defects linked to these disorders, identifying and interpreting the clinical significance of genetic variants remains challenging.

“Things have started to plateau a little bit, so leveraging AI or machine learning or new methods to further understand different, more complicated genetic inheritance patterns certainly is… [helpful],” DiGiacomo said.

AI tools can support genetic interpretation through computational analyses that model how specific genetic changes may alter downstream biological processes, including RNA expression or protein structure. In conditions where rare genetic variants are detected, these tools may help clinicians better determine whether a mutation is likely to contribute to disease.

Advances in genetics are also influencing treatment strategies across allergy and immunology. As researchers better characterize the molecular pathways underlying immune-mediated disease, new biologic therapies are being developed to target specific components of those pathways. DiGiacomo noted that conditions such as hereditary angioedema (HAE) illustrate how improved understanding of disease biology can translate into targeted therapies that affect pathways involved in bradykinin metabolism and contact system activation.

These advances have led to the development of monoclonal antibodies, RNA-based therapeutics, and other targeted treatments designed to modulate specific immune pathways, DiGiacomo said. In some cases, emerging therapies are also expanding treatment options beyond injectable medications to oral alternatives or novel molecular strategies.

DiGiacomo suggested that continued progress in genetic testing and biomarker research could eventually shift allergy and immunology toward more predictive and preventative models of care. Identifying patients who are genetically predisposed to immune disorders or allergic diseases may allow clinicians to intervene earlier in the disease course.

New diagnostic approaches, including advanced immune profiling techniques such as detailed flow cytometry panels and cytokine analysis, are also helping clinicians identify the immune pathways driving disease in individual patients.

“Genetic testing has been easier to order. It's become more available, and it's been integrated specifically in the immunology realm,” DiGiacomo said. “Understanding the basic aspects of how to order it, why you're ordering it, how to counsel patients, how to interpret some of those findings, and how to leverage it to best treat the patient should definitely be integrated into teaching.”

DiGiacoma D. Practical and Hands-On Guidance Regarding Genetic Testing. Presented at the American Academy of Allergy, Asthma, & Immunology (AAAAI) on February 27 – March 2, 2026

Invitae Hereditary Angioedema Panel - Clinical Genetic Test - GTR - NCBI. Nih.gov. Published 2021. Accessed March 11, 2026. 

https://www.ncbi.nlm.nih.gov/gtr/tests/593409/

At AAAAI 2026, DiGiacomo discussed how artificial intelligence, genetic testing, and biomarkers could improve diagnosis and precision care.


Caleb Alexander, MD, MS, is a professor of epidemiology and medicine at Johns Hopkins University School of Medicine and co-founder and principal of Stage Analytics.

Alexander discusses his recent study comparing 61 trials of 4 main GLP-1 RAs, highlighting their increased efficacy for weight loss in female patients.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

GLP-1 RA Effects are Largely Homogeneous but Stronger in Women than Men, With Caleb Alexander, MD, MS

In this episode, experts discuss solitary confinement, aging in prison, and gaps in care for incarcerated populations.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Medical Ethics Unpacked

Medical Ethics Unpacked is a regular multimedia series hosted by Dominic Sisti, PhD, and Steve Levine, MD, spotlighting a spectrum of topics within the field of medical ethics. Throughout the year, hosts will sit down for an in-depth discussion on a specific ethical dilemma within modern healthcare, with some episodes also featuring a special guest. 

Check back throughout the year for discussions on a variety of topics, including data privacy in health apps, euthanasia and medical assistance in dying, reproductive rights and technologies, and more!

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Medical Ethics Unpacked: Ethical Challenges of Carceral Healthcare

Explore emerging IBD treatments—TL1A blockers, microRNA, stem cells—and new small-bowel imaging, plus team-based care improving access.

UChicago Advances IBD Trials With Focus on Microbiome and Access

Senior Allergy Dietitian at the Royal Children’s Hospital, Clinician-Scientist Fellow at MCRI & Honorary Senior Research Fellow at Melbourne University,

McWilliam discussed findings from the TreEat study at AAAAI 2026.

Multi-Nut OFC Feasible, Comparable to Home Introduction in Infants With Peanut Allergy, With Vicki McWilliam, MND, PhD

Salvatore Viscomi, MD, is the chief executive officer of Carna Health.

Salvatore Viscomi, MD on closing CKD health disparities through community testing, AI equity, and accessible care for underserved populations.

Enhancing CKD Early Detection in High-Risk Populations Via Community Programs, AI, With Salvatore Viscomi, MD

María José Torres Jaén, MD, PhD, from Hospital Regional Universitario de Málaga.

At AAAAI 2026, Torres highlighted phase 3 peach immunotherapy research, nanostructure preclinical models, and a phase 2 prebiotic trial for LTP allergy.

Immunomodulation for Plant-Based Food Allergy, With María José Torres Jaén, MD, PhD

This interview highlights the significance of the potential FDA approval of imsidolimab for patients with generalized pustular psoriasis (GPP).

What Is the Significance of New Data on Imsidolimab for GPP? With Neal Bhatia, MD

Bernard Kadosh, MD, is the medical director of the ventricular assist device and cardiogenic shock programs at NYU Langone Health.

Kadosh and Gorodeski discuss the value of including non-specialists in HF care and the challenges of prescribing 4 pills in a time of increasing medical distrust.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Multidisciplinary Care and Addressing Pill Burden in HF, With Bernard Kadosh, MD, and Eiran Gorodeski, MD, MPH

from Charité-Universitätsmedizin Berlin.

At AAAAI 2026, Magerl discusses phase 2 data showing BW-20805 reduced hereditary angioedema attacks by up to 100% with dosing intervals of up to 6 months.

BW-20805 Reduces HAE Attacks in Phase 2 Trial, With Markus Magerl, MD

Mohan Satish, MD, is a cardiology fellow at NYP-Weill Cornell.

Satish discusses his recent study highlighting significant increases in first AMI in-hospital mortality among young adults, particularly in women.

Latest News

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

Is Expedited Kidney Donation More Effective Than In-Sequence?

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

Omalizumab or Oral Immunotherapy for Food Allergy, With Robert Wood, MD

AI, Genetic Testing May Advance Precision Care in Immunology, With Daniel DiGiacomo, MD